Want to see RPID full AI Analyst Report?
RPID Stock Chart & Stats
$1.99
$0.00(0.00%)
At close: 4:00 PM EDT
$1.99
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.66 - $4.94
Previous CloseN/A
Volume24.17K
Average Volume (3M)253.56K
Market Cap
$86.19M
Enterprise Value$87.22
Total Cash (Recent Filing)$19.77M
Total Debt (Recent Filing)$23.48M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding45,322,280
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.67Price Target Upside235.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$39.33M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthStrong consumables momentum and 14% recurring revenue growth reflect a high-frequency, sticky revenue stream tied to each instrument. As the installed base and validations scale, consumables generate predictable, repeatable cash flows and margin leverage that support long‑term revenue visibility.
Improving Gross Margin TrajectoryMargin expansion from negative levels to a positive 15% and near‑term targets above 20% indicate structural improvement in product and service economics. Sustained margin gains reduce the scale required for breakeven and underpin management's multi‑year plan to reach positive cash flow and higher profitability.
Validation And Installed Base MomentumFaster validation converts placed systems into recurring consumable users, shortening time to revenue capture from installations. Higher validation throughput increases visibility into future consumable demand and supports economies of scale in service and manufacturing, strengthening long‑term unit economics.
Bears Say
Persistent Operating LossesLarge and ongoing operating losses show the business has not yet achieved operating leverage despite revenue gains. Continued negative profitability consumes capital, constrains reinvestment, and lengthens the period before the company can self‑fund growth or withstand adverse market conditions.
Negative Cash Flow And Financing ReliancePersistent negative operating and free cash flow means the company depends on external financing and milestone debt draws to sustain operations. Reliance on debt tranches and potential warrant proceeds elevates execution and refinancing risk, potentially diluting stakeholders or constraining strategic choices.
Rising Leverage And Weakened Balance SheetA step‑up in leverage while profitability remains negative reduces financial flexibility and increases refinancing and covenant risk. Higher debt relative to shrinking equity limits the firm's ability to absorb shocks or invest opportunistically as it approaches the critical path to sustained positive cash generation.
Rapid Micro Biosystems News
RPID FAQ
What was Rapid Micro Biosystems’s price range in the past 12 months?
Rapid Micro Biosystems lowest stock price was $1.66 and its highest was $4.94 in the past 12 months.
What is Rapid Micro Biosystems’s market cap?
Rapid Micro Biosystems’s market cap is $86.19M.
When is Rapid Micro Biosystems’s upcoming earnings report date?
Rapid Micro Biosystems’s upcoming earnings report date is Nov 05, 2026 which is in 86 days.
How were Rapid Micro Biosystems’s earnings last quarter?
Rapid Micro Biosystems released its earnings results on Aug 07, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.243 by -$0.027.
Is Rapid Micro Biosystems overvalued?
According to Wall Street analysts Rapid Micro Biosystems’s price is currently Undervalued.
Does Rapid Micro Biosystems pay dividends?
Rapid Micro Biosystems does not currently pay dividends.
What is Rapid Micro Biosystems’s EPS estimate?
Rapid Micro Biosystems’s EPS estimate is -0.2.
How many shares outstanding does Rapid Micro Biosystems have?
Rapid Micro Biosystems has 45,322,280 shares outstanding.
What happened to Rapid Micro Biosystems’s price movement after its last earnings report?
Rapid Micro Biosystems reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.243. Following the earnings report the stock price went down -16.827%.
Which hedge fund is a major shareholder of Rapid Micro Biosystems?
Currently, no hedge funds are holding shares in RPID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapid Micro Biosystems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (235.01% Upside)
$6.67 (235.01% Upside)
Hedge Fund Trend
Decreased
By 5.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.00%
Trailing 12-Months
Company Description
Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
RPID Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.View all RPID earnings summariesRPID Stock 12 Month Forecast
Average Price Target
$6.67
▲(235.01% Upside)
Technical Analysis
Ownership Overview
33.02% Insiders
3.09% Mutual Funds
2.18% Other Institutional Investors
59.19% Public Companies and
Individual Investors